- Report
- March 2025
- 50 Pages
Italy
From €543EUR$600USD£466GBP
- Report
- March 2025
- 50 Pages
United Kingdom
From €543EUR$600USD£466GBP
- Report
- March 2025
- 50 Pages
Germany
From €543EUR$600USD£466GBP
- Report
- March 2025
- 50 Pages
France
From €543EUR$600USD£466GBP
- Report
- March 2025
- 50 Pages
Mexico
From €543EUR$600USD£466GBP
- Report
- March 2025
- 50 Pages
Canada
From €543EUR$600USD£466GBP
- Report
- March 2025
- 50 Pages
United States
From €543EUR$600USD£466GBP
- Report
- September 2024
- 115 Pages
Global
From €3621EUR$4,000USD£3,108GBP
- Report
- August 2023
- 1300 Pages
Global
From €8057EUR$8,900USD£6,915GBP
- Report
- August 2023
- 300 Pages
Africa, Middle East
From €4436EUR$4,900USD£3,807GBP
- Report
- August 2023
- 300 Pages
Latin America
From €4436EUR$4,900USD£3,807GBP
- Report
- August 2023
- 300 Pages
Asia Pacific
From €4436EUR$4,900USD£3,807GBP
- Report
- August 2023
- 300 Pages
Europe
From €4436EUR$4,900USD£3,807GBP
- Report
- August 2023
- 51 Pages
South Korea
From €543EUR$600USD£466GBP
- Report
- August 2023
- 51 Pages
India
From €543EUR$600USD£466GBP
- Report
- August 2023
- 51 Pages
Mexico
From €543EUR$600USD£466GBP
- Report
- August 2023
- 51 Pages
Australia
From €543EUR$600USD£466GBP
- Report
- August 2023
- 51 Pages
Japan
From €543EUR$600USD£466GBP
- Report
- August 2023
- 51 Pages
United States
From €543EUR$600USD£466GBP
- Report
- August 2023
- 51 Pages
Argentina
From €543EUR$600USD£466GBP

The Artificial Pancreas is a medical device that uses biomaterials to regulate blood glucose levels in people with diabetes. It is composed of a continuous glucose monitor (CGM) and an insulin pump, which are connected to a computer algorithm that automatically adjusts insulin delivery. The Artificial Pancreas is designed to mimic the natural pancreas, which produces insulin in response to changes in blood glucose levels. The device is intended to reduce the burden of diabetes management and improve glycemic control.
The Artificial Pancreas market is growing rapidly, driven by increasing prevalence of diabetes, technological advancements, and increasing awareness of the benefits of the device. The market is expected to be further driven by increasing investments in research and development, and the introduction of new products.
Some of the key players in the Artificial Pancreas market include Medtronic, Johnson & Johnson, Insulet Corporation, Dexcom, Tandem Diabetes Care, and Bigfoot Biomedical. Show Less Read more